Risk Prediction for Gynecological Cancer

Dear Colleagues,

Risk prediction for gynaecological cancer is crucial for the early prevention, timely diagnosis, and effective treatment of cervical, endometrial and tubo-ovarian cancers. These cancers pose significant health threats to women worldwide, and understanding risk factors and tools to achieve early diagnosis can help researchers to reduce their incidence and mortality rates. Cervical cancer risk prediction relies heavily on screening and vaccination. Human papillomavirus (HPV) is the primary cause, so regular pap smears and HPV testing are essential, and screening programs and new assessments should be incorporated in clinical practice worldwide. Endometrial cancer, primarily affecting postmenopausal women, is often linked to obesity, diabetes, hypertension, and hormonal imbalances. Predictive models focus on these factors,  as well as genetic predispositions and lifestyle choices. Early detection through symptom awareness and ultrasound assessment, both combined with timely endometrial biopsies, is crucial, and in this context, a hysteroscopic approach is of utmost importance. Ovarian cancer presents the greatest challenge due to its often-late diagnosis and subtle early symptoms. Risk factors include age, a family history of ovarian or breast cancer, and genetic mutations like BRCA1 and BRCA2. Risk prediction involves genetic testing, particularly for those with a family history, and regular pelvic exams. Prophylactic surgeries (such as salpingo-oophorectomy) are considered for high-risk individuals. Research into biomarkers and advanced imaging techniques continues to evolve, aiming to improve early detection rates. Integrating these risk prediction strategies into routine healthcare can significantly enhance the prevention and early diagnosis of gynaecological cancers. This Special Issue will highlight recent advances in the context of diagnosis, treatment, and the prediction of prognosis for these malignancies.

Dr. Federico Ferrari
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cervical cancer
• endometrial cancer
• tubo-ovarian cancer
• diagnosis
• treatment
• prognosis